Short Interest in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Expands By 59.6%

Posted by Teresa Graham on Feb 1st, 2026

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 10,560 shares, a growth of 59.6% from the December 31st total of 6,618 shares. Based on an average daily volume of 15,067 shares, the days-to-cover ratio is presently 0.7 days. Approximately 3.8% of the shares of the stock are sold short. Approximately 3.8% of the shares of the stock are sold short. Based on an average daily volume of 15,067 shares, the days-to-cover ratio is presently 0.7 days.

ProShares UltraShort Nasdaq Biotechnology Price Performance

ProShares UltraShort Nasdaq Biotechnology stock traded up $0.18 during midday trading on Friday, reaching $8.99. 6,652 shares of the stock traded hands, compared to its average volume of 16,678. The stock’s fifty day moving average is $9.27 and its 200-day moving average is $11.84. ProShares UltraShort Nasdaq Biotechnology has a 12 month low of $8.37 and a 12 month high of $25.87.

ProShares UltraShort Nasdaq Biotechnology Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Stockholders of record on Wednesday, December 24th were given a dividend of $0.1026 per share. This represents a $0.41 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date was Wednesday, December 24th.

Institutional Investors Weigh In On ProShares UltraShort Nasdaq Biotechnology

A hedge fund recently bought a new stake in ProShares UltraShort Nasdaq Biotechnology stock. Csenge Advisory Group acquired a new position in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 12,421 shares of the company’s stock, valued at approximately $163,000. Csenge Advisory Group owned approximately 6.54% of ProShares UltraShort Nasdaq Biotechnology as of its most recent SEC filing.

ProShares UltraShort Nasdaq Biotechnology Company Profile

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.